Clinical Trials
16 trialsNCT07217171 2026-06-03
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United, Inc
Phase 1 Recruiting
NCT07124000 2026-06-01
DP-04
AstraZeneca
Recruiting
NCT07602842 2026-05-22
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
InduPro, Inc.
Phase 1/2 Not yet recruiting
NCT06270706 2026-04-20
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
Phase 1 Recruiting
NCT05461430 2026-04-13
TraveraRTGx
Travera Inc
Completed
NCT05858736 2026-04-09
PRESERVE-009
OncoC4, Inc.
Phase 1 Active not recruiting
NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT06526819 2026-02-27
SMP-3124LP in Adults With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
Phase 1/2 Recruiting
NCT05551117 2026-02-09
Tamarack
MacroGenics
Phase 2 Terminated
NCT06910137 2026-01-08
An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)
Incyte Corporation
Available
NCT05544929 2026-01-06
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Phase 1 Active not recruiting
NCT04472429 2025-11-03
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
Incyte Corporation
Phase 3 Completed
NCT04272034 2025-10-16
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT05941507 2025-09-24
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2 Recruiting
NCT02628067 2025-09-22
KEYNOTE 158
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT04635423 2025-08-11
V503-064
Merck Sharp & Dohme LLC
Phase 3 Completed